Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.49 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884741 | 0.89 | GRIA1 (0.53) | GRIA1GRIA3PDE4DUSP30RET | |
| SCHEMBL1880094 | 0.87 | GRIA1 (0.50) | GRIA1GRIA3PDE4D | |
| SCHEMBL1883493 | 0.83 | GRIA1 (0.60) | GRIA1GRIA3PDE4D | |
| SCHEMBL1879971 | 0.81 | GRIA1 (0.57) | GRIA1GRIA3PDE4DKDM4E | |
| SCHEMBL1882804 | 0.80 | GRIA1 (0.55) | GRIA1GRIA3PDE4DRET | |
| SCHEMBL1879614 | 0.80 | GRIA1 (0.55) | GRIA1GRIA3PDE4DPKM | |
| SCHEMBL1885896 | 0.72 | GRIA1 (0.68) | GRIA1GRIA3PDE4DKDM4EPKM | |
| SCHEMBL23531667 | 0.71 | KDM4E (0.52) | GPR119USP30USP7KDM4EPKM | |
| SCHEMBL2582899 | 0.70 | GPR119 (0.53) | GPR119RETKDM4EPKM | |
| SCHEMBL1885015 | 0.70 | GRIA1 (0.66) | GRIA1GRIA3PDE4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939549-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-7759367-B2 | 1,2-dihydropiridin-2-one compounds such as 3-(2-cyanophenyl)-1-phenyl-5-(2-pyridyl)-1,2-dihydropyridin-2-one, used as immunomodulators or antiinflammatory agents, and for the prevention or treatment of neurodegenerative diseases, such as demyelinating disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2177520-A1 | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2010-04-21 | — | — | EP | disclosed |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | NAGATO SATOSHI | 2009-11-05 | — | — | US | disclosed |
| US-7563811-B2 | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-2053041-A2 | 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1465626-B1 | PHARMACEUTICAL COMPOSITIONS (KIT) COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY (OR AN ANTIINFLAMMATORY) AGENT AND THEIR USES | EISAI R&D MAN CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-20090275751-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, MANUFACTURING METHOD THEREOF AND USE THEREOF | GRIK1, GRIK2, GRIK5 | GRIA1 20/4885GRIA3 28/4885PDE4D 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.